SCYNEXIS (SCYX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members, executive officers, and the auditor present.
Formal business followed the agenda outlined in the notice and proxy statement.
Corporate governance
Quorum established with proxies for 74.49% of outstanding shares, allowing business to proceed.
No additional shareholder proposals were filed; business limited to six proxy proposals.
Scott Sukenick appointed as Inspector of Election for the meeting.
Shareholder proposals
Six proposals presented: election of directors, ratification of auditor, advisory vote on executive compensation, advisory vote frequency, amendment to equity incentive plan, and amendment to certificate of incorporation to increase authorized shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SCYNEXIS
- Q2 2026 net income was $7.4M, with strong cash reserves and key clinical milestones ahead.SCYX
Q2 2026 - Shareholders approved a reverse stock split and reduction of authorized shares.SCYX
EGM 2026 - Q1 2026 featured a major acquisition, $21.3M net loss, and cash runway extended to mid-2029.SCYX
Q1 2026 - Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing - Annual meeting seeks approval for director elections, equity plan expansion, and capital increase.SCYX
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing - Shareholders will vote on director elections, compensation, equity plan, and capital structure changes.SCYX
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing